Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma

Interventions: Behavioral: The risk assessment questionnaire
Other: Blood specimens
Other: tumor tissue samples will be requested

First Posted Date: 2013-11-14

Last Posted Date: 2024-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 600

Registration Number: NCT01983410

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 10 locations

Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis

Completed

Conditions: Brain Cancer

Interventions: Procedure: MRI

First Posted Date: 2013-11-03

Last Posted Date: 2022-12-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01974804

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

Phase 2

Completed

Conditions: Advanced Epithelial Ovarian
Primary Peritoneal Carcinoma
Recurrent Epithelial Ovarian
Fallopian Tube

Interventions: Drug: Enzalutamide

First Posted Date: 2013-11-03

Last Posted Date: 2023-04-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 59

Registration Number: NCT01974765

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 3 locations

Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery

Phase 3

Completed

Conditions: Pain

Interventions: Drug: Dexmedetomidine
Drug: Placebo

First Posted Date: 2013-10-31

Last Posted Date: 2024-02-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 333

Registration Number: NCT01973452

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, New York, United States

and more 1 locations

Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material

Phase 2

Completed

Conditions: Esophageal Adenocarcinoma

Interventions: Device: MatriStem PSM

First Posted Date: 2013-10-28

Last Posted Date: 2023-11-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 78

Registration Number: NCT01970306

Locations: 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Phase 1

Completed

Conditions: EGFR-Mutant Lung Cancer

Interventions: Drug: erlotinib

First Posted Date: 2013-10-22

Last Posted Date: 2018-11-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 53

Registration Number: NCT01967095

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States

and more 2 locations

Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer

Not Applicable

Active, not recruiting

Conditions: Breast Cancer

Interventions: Behavioral: Aerobic Training
Behavioral: Educational Information
Behavioral: Supervised Home Based Training

First Posted Date: 2013-09-17

Last Posted Date: 2024-07-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 144

Registration Number: NCT01943695

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

Phase 1

Completed

Conditions: Intrahepatic Cholangiocarcinoma
Peripheral Cholangiocarcinoma
Cholangiocellular Carcinoma) (ICC)
Cholangiolar Carcinoma

Interventions: Procedure: Liver resection and placement of hepatic artery infusion pump
Drug: FLOXURIDINE
Drug: DEXAMETHASONE
Drug: GEMCITABINE

First Posted Date: 2013-09-10

Last Posted Date: 2020-09-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 8

Registration Number: NCT01938729

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT

Phase 3

Completed

Conditions: Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have

Interventions: Drug: Topical Dapsone 5% Gel
Other: Moisturizer
Drug: oral antibiotics

First Posted Date: 2013-08-29

Last Posted Date: 2017-01-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01931150

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Leukemia

Interventions: Drug: Daunorubicin
Drug: Vincristine
Drug: Prednisone
Drug: PEG-Asparaginase
Drug: Methotrexate
Drug: 6-MP (6-Mercaptopurine)
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Leucovorin
Drug: Dexamethasone
Other: Blood draw
Device: CT/PET scans

First Posted Date: 2013-08-12

Last Posted Date: 2023-10-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT01920737

Locations: 🇺🇸
Weill Cornell Medical Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy